U.S. Tobacco Stock News

Recent coverage of American Superconductor (AMSC) has focused on its shift toward power systems for energy grids and naval technology, where consistent double-digit sales growth and stronger cash generation are drawing fresh investor attention. See our latest analysis for American Superconductor. Even after a sharp 10.2% one day share price decline and a 12.3% year to date share price pullback to about US$27.70, American Superconductor still carries a 57.9% one year total shareholder return...

In late February 2026, Transocean reported a stronger contract backlog of about US$6.10 billion, better-than-expected first-quarter revenue guidance, continued debt reduction, and new offshore drilling wins, while a potential merger with Valaris attracted legal scrutiny over fairness to shareholders. These updates point to improving operational resilience and financial flexibility for Transocean, even as some market commentators highlight concerns about its leverage and position relative to...

Why RONN Stock Is On Traders’ Radar RONN (RONN) has drawn attention after sharp recent swings, with returns around 99% over the past week and past 3 months, putting this small zero emission vehicle developer back in focus for speculative investors. See our latest analysis for RONN. That surge in recent share price returns over the past week and past quarter comes after a much tougher stretch, with the 1 year total shareholder return still showing a 50% decline. This highlights how quickly...

In late February 2026, Grindr Inc. reported fourth-quarter 2025 sales of US$125.97 million and net income of US$20.26 million, and full-year 2025 sales of US$439.90 million with net income of US$94.75 million, while also raising its 2026 revenue outlook to more than US$528 million. At the same time, Grindr expanded its equity buyback authorization to US$900 million and extended the program through March 2029, underlining management’s confidence in the company’s cash generation and long-term...

Aura Minerals Inc. recently reported 2025 results showing total sales of US$921.73 million and a net loss of US$79.34 million, alongside 278,296 gold equivalent ounces sold and a Board-approved dividend of US$0.66 per share (US$55.12 million in total) to be paid in March 2026. The company also released an updated Borborema feasibility study that lifted Probable Reserves to about 1.48 million ounces of gold, extended mine life to 20.5 years and supported stronger project economics, while...

Ryan Specialty Holdings (RYAN) is back in focus after reporting 2025 revenue of more than US$3.05b, completing five acquisitions, and launching its three year Empower Program to streamline operations and cut costs. See our latest analysis for Ryan Specialty Holdings. Despite the Empower Program and recent acquisitions getting attention, Ryan Specialty Holdings’ 1 day share price return of 1% and 7 day share price return of 0.9% sit against a 30 day share price decline of 16.4%, a year to date...

If you are wondering whether Bel Fuse shares still offer value after a strong run, this article explains what the current price might be implying about the business. The stock closed at US$172.94 recently, with a 7 day return of an 18.4% decline and a 30 day return of a 16.0% decline, while the 1 year return sits at 119.7% and the 3 year return is very large. These price moves sit against a backdrop of ongoing attention on Bel Fuse within the tech sector, as investors reassess companies that...

Bio-Techne recently presented at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at the Boston Marriott Copley Place Hotel in Boston, Massachusetts, sharing its latest updates with investors and industry participants. This conference appearance came shortly after broader healthcare sector concerns tied to a weak February jobs report, linking Bio-Techne’s story more closely to macroeconomic sentiment than to company-specific developments. We’ll now examine how sector-wide...

If you are wondering whether Microsoft is still fairly priced after its long run as a market heavyweight, looking closely at its current valuation can help you decide how it might fit into your portfolio. The stock last closed at US$408.96, with returns of 2.6% over the past 7 days, 1.9% over the past 30 days, a year-to-date return of a 13.5% decline, and 8.4% over the past year. The 3-year and 5-year returns sit at 64.9% and 81.5% respectively. Recent headlines around Microsoft have focused...

In early March 2026, Kennametal faced pressure after a weaker-than-expected U.S. February jobs report showed the manufacturing sector losing 12,000 positions, raising concerns about softer industrial activity. This macro shock matters because Kennametal’s tools and materials are closely tied to manufacturing demand, making labor-market softness a key watchpoint for its outlook. Against this backdrop of softer manufacturing employment, we’ll now examine how the latest data may influence...

In recent weeks, Badger Meter has faced cautious analyst sentiment ahead of an upcoming earnings release that is expected to show year-over-year EPS decline despite higher revenue, alongside insider share sales by senior executives Fred Begale and Kimberly Stoll over the past year. This combination of softer earnings expectations, premium valuation concerns, and ongoing insider selling has sharpened investor focus on how durable Badger Meter’s growth and profitability thesis really is. Now...

On February 24, 2026, Brady Corporation’s board declared a US$0.245 per-share dividend on Class A common stock, payable April 30, 2026, to shareholders of record as of April 9, 2026. This dividend decision comes alongside multi-year growth in sales, earnings, and free cash flow, underscoring Brady’s capacity to return cash to investors. We’ll now examine how Brady’s dividend declaration, against a backdrop of solid multi-year earnings and cash flow growth, influences its investment...

Mirum Pharmaceuticals (MIRM) is back in focus after the company completed enrollment for its Phase 3 AZURE-1 trial and finished screening for the Phase 3 AZURE-4 study of brelovitug in chronic hepatitis delta virus. See our latest analysis for Mirum Pharmaceuticals. The brelovitug trial milestones come after a busy few weeks that included Mirum’s fourth quarter and full year 2025 results, a shelf registration filing and a high profile appearance at a major healthcare conference. Despite a...

Dividend affirmation amid sectorwide credit jitters TriCo Bancshares (TCBK) recently declared a quarterly cash dividend of $0.36 per share, even as regional bank stocks, including TriCo, have come under pressure from concerns around private credit exposures. The dividend, payable on March 20, 2026 to shareholders of record on March 6, 2026, is the company’s 146th consecutive quarterly cash distribution to investors. See our latest analysis for TriCo Bancshares. TriCo’s recent dividend...

Vericel (VCEL) is back in focus after the FDA approved commercial manufacturing of its MACI cartilage repair therapy at the company’s Burlington, Massachusetts facility, a milestone tied directly to future production capacity. See our latest analysis for Vericel. Even with the FDA clearance for MACI manufacturing and recent earnings and guidance updates, Vericel’s share price has cooled, with a 1-year total shareholder return decline of 31.98%, although the 3-year total shareholder return of...

Recent trading in Huron Consulting Group (HURN) has drawn attention after a one-month return of about a 15% decline and a past three-month return of about a 15% decline, prompting closer scrutiny of its fundamentals. See our latest analysis for Huron Consulting Group. At a share price of $144.83, Huron’s recent 30 and 90 day share price returns of about a 15% decline sit in contrast with a 1 year total shareholder return of roughly a 3% decline and 3 and 5 year total shareholder returns of...

In a recent filing, Eva Live announced it secured $7 million in growth financing, another step closer to advancing the company’s broader investment narrative.

Recent share performance and business snapshot With no single headline event driving attention to Veris Residential (VRE), the recent share performance itself is the focus, as the stock shows double digit returns over the past month and past 3 months. Veris Residential is a real estate investment trust focused on Class A multifamily properties in the Northeast. It uses a technology enabled, vertically integrated platform to manage, operate, acquire, and develop its portfolio for residents and...

Corebridge Financial (CRBG) is back in focus after reporting a record US$41.7b in total premiums and deposits for 2025, alongside stronger capital and liquidity metrics that could influence how investors view the stock. See our latest analysis for Corebridge Financial. Despite the record premiums and deposits, Corebridge Financial’s recent share price performance has been weak, with a 30 day share price return of an 18.65% decline and a year to date share price return of a 16.53% decline,...

Alkermes plc recently reported that fourth‑quarter 2025 revenue slipped to US$384.55 million, with net income and earnings per share also lower year over year, while the Board confirmed CEO Richard Pops will retire in July 2026 and current COO Blair Jackson will assume the CEO role in August 2026. Alongside these results, Alkermes advanced its orexin agonist ALKS 2680 into Phase 3 trials for narcolepsy type 1, highlighting how its neuroscience pipeline is becoming increasingly central to the...

Certara recently highlighted that its Simcyp physiologically-based pharmacokinetic modeling was accepted by the U.S. FDA in place of multiple clinical pharmacology studies to support the new drug application for asciminib (Scemblix®), an allosteric BCR::ABL1 inhibitor for Chronic Myeloid Leukemia. This decade-long modeling effort, which replaced at least ten dedicated clinical studies and informed dosing and drug-interaction decisions, underscores how biosimulation can cut development costs...

Azenta (AZTA) has drawn attention after recent share price pressure, with the stock down about 27% year to date and roughly 44% over the past year. This has prompted investors to reassess its fundamentals. See our latest analysis for Azenta. The recent pressure on Azenta’s share price, including a 1-day share price return of negative 1.98% and a 30-day share price return of negative 15.39%, sits on top of a 1-year total shareholder return of negative 44.37%. This signals that momentum has...

What triggered fresh interest in Xeris Biopharma Holdings (XERS)? Xeris Biopharma Holdings (XERS) has drawn fresh attention after reporting fourth quarter and full year 2025 results that moved from loss to profit, paired with new 2026 revenue guidance and a US$40.7 million shelf registration filing. See our latest analysis for Xeris Biopharma Holdings. Despite Xeris Biopharma Holdings posting improved earnings and setting 2026 revenue guidance, recent share price returns have been weak, with...

MarketAxess Holdings Inc. recently appointed William Quan as Chief Technology Officer, tasking him with modernizing its global technology platforms and embedding AI and advanced data capabilities across the business. By bringing in a leader with deep experience in electronic trading and AI-driven platforms from firms like Amazon Web Services, J.P. Morgan, and Deutsche Bank, MarketAxess is signaling a stronger push to enhance its bond-trading technology and product innovation. With William...